 Connection
Jason Glanz to Vaccines, Attenuated
This is a "connection" page, showing publications Jason Glanz has written about Vaccines, Attenuated.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.698 |
|
|
|
-
Newcomer SR, Daley MF, Narwaney KJ, Xu S, DeStefano F, Groom HC, Jackson ML, Lewin BJ, McLean HQ, Nordin JD, Zerbo O, Glanz JM. Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. Pediatr Infect Dis J. 2020 03; 39(3):247-253.
Score: 0.618
-
Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf. 2018 01; 27(1):59-68.
Score: 0.033
-
Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, Jackson LA, DeStefano F. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014 Feb 06; 370(6):513-9.
Score: 0.025
-
Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA, Hambidge SJ, Glanz JM, Klein NP, Weintraub E. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012 Feb 08; 307(6):598-604.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|